Skip to Content
Due to a recent surge in pediatric RSV and flu, we are allowing only visitors 18 years of age and older in our general inpatient (hospital) settings at this time for the safety of our patients, in line with Illinois Department of Public Health guidance. Read More

Skin/Melanoma Trials

EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing)
Aims: This study will test which treatment to receive first and the potential sequence of treatments for melanoma
Diagnosis: Melanoma
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH17-194
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes

EA6141: A Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma  
Aims: The purpose of this research study is to compare any good and bad effects of giving ipilimumab, nivolumab and GM-CSF (Sargramostim) at the same time compared to just ipilimumab and nivolumab. 
Diagnosis:  Melanoma
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH16-200
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

UV1-202: Randomized Phase II, Open-label, Active-controlled, Multicenter Study Investigating the Efficacy and Safety of UV1 Vaccincation in Combination with Nivolumab and Ipilumumab as First-line Treatment of Patients with Unresectable or Metastatic Melanoma  
Aims: The purpose of this research study is to compare any good and bad effects of giving the UV1 vaccine in addition to the treatment of nivolumab and ipilimumab
Diagnosis:  Melanoma
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH20-329
Sponsor: Ultimovics ASA
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes